Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02969031 · ClinicalTrials.gov registry record · NA

Improving Communication Between Cancer Patients & Oncologists

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
148
Enrollment target

NCT02969031 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 148 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02969031, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
148 participants
Enrollment target

Study Summary

The overarching goal of this project is to improve communication between oncologists and their patients by ensuring that the patient's voice is heard in the medical encounter. Thus, the hope is to improve the experience for patients living with cancer. The investigators seek to accomplish this goal by providing oncologists communication skills training that includes feedback on their own audio-recorded conversations. The feedback will come from two sources: 1) Professional research assistant coders who will identify objective learning opportunities based on specific coding criteria and 2) Trained patient reviewers who will listen to the recordings and offer their own, subjective feedback at key moments in the encounters.

Interventions

  • BEHAVIORAL Enhanced SCOPE training
  • BEHAVIORAL Standard Communication training

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2017-02-14
Est. Completion 2018-08-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT02969031

The ClinicalTrials.gov registry entry for NCT02969031 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Enhanced SCOPE training is the first listed.

NCT02969031 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02969031 about?

NCT02969031 is a clinical study titled "Improving Communication Between Cancer Patients & Oncologists". The overarching goal of this project is to improve communication between oncologists and their patients by ensuring that the patient's voice is heard in the medical encounter. Thus, the hope is to improve the experience for patients living with cancer. The investigators seek to accomplish this goal ...

What is the current status of trial NCT02969031?

This trial is currently completed. It is a NA study. The enrollment target is 148 participants. The study started on 2017-02-14. Estimated completion is 2018-08-31.

What interventions are being tested in trial NCT02969031?

The interventions under investigation include: Enhanced SCOPE training (BEHAVIORAL), Standard Communication training (BEHAVIORAL).

Who is sponsoring clinical trial NCT02969031?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.